Cargando…

Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

BACKGROUND: Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related death and represents a major health burden worldwide. Current therapies for NSCLC include chemotherapy, immunotherapy, and targeted molecular agents such as tyrosine kinase inhibitors and epigenetic drugs such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dominici, Claudia, Sgarioto, Nicolas, Yu, Zhenbao, Sesma-Sanz, Laura, Masson, Jean-Yves, Richard, Stéphane, Raynal, Noël J.-M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948358/ https://www.ncbi.nlm.nih.gov/pubmed/33691794 http://dx.doi.org/10.1186/s13148-021-01037-1

Ejemplares similares

Genome-wide R-loop analysis defines unique roles for DDX5, XRN2, and PRMT5 in DNA/RNA hybrid resolution
por: Villarreal, Oscar D, et al.
Publicado: (2020)

Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids
por: Mersaoui, Sofiane Y, et al.
Publicado: (2019)

Arginine Methylation by PRMT1 Regulates Muscle Stem Cell Fate
por: Blanc, Roméo Sébastien, et al.
Publicado: (2017)

PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
por: Carter, Jack, et al.
Publicado: (2023)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
por: Sun, Yutong, et al.
Publicado: (2019)

PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
por: Huang, Yuhan, et al.
Publicado: (2023)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis
por: Yang, Tianshu, et al.
Publicado: (2023)

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
por: Lui, Goldie Y.L., et al.
Publicado: (2020)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

PRMT5 is essential for B cell development and germinal center dynamics
por: Litzler, Ludivine C., et al.
Publicado: (2019)

Target engagement imaging of PARP inhibitors in small-cell lung cancer
por: Carney, Brandon, et al.
Publicado: (2018)

Detection of PRMT1 inhibitors with stopped flow fluorescence
por: Qian, Kun, et al.
Publicado: (2018)

Arginine methylation of hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage
por: Gurunathan, Gayathri, et al.
Publicado: (2015)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
por: Waissi, Waisse, et al.
Publicado: (2021)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4)
por: Gunnell, Emma A., et al.
Publicado: (2020)

Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023)

PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells
por: Bajbouj, Khuloud, et al.
Publicado: (2021)

Design and Synthesis of Novel PRMT1 Inhibitors and Investigation of Their Effects on the Migration of Cancer Cell
por: Wang, Caijiao, et al.
Publicado: (2022)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
por: Matsuno, Yusuke, et al.
Publicado: (2018)

Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6
por: Sivakumaran, Haran, et al.
Publicado: (2013)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
por: Knelson, Erik H., et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Development of Macrocyclic PRMT5–Adaptor Protein Interaction Inhibitors
por: Krzyzanowski, Adrian, et al.
Publicado: (2022)

Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer
por: Brobbey, Charles, et al.
Publicado: (2023)

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines
por: Camero, Simona, et al.
Publicado: (2018)

Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation
por: Huang, Duen-Yi, et al.
Publicado: (2020)

Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer
por: Chen, Yingqing, et al.
Publicado: (2022)

PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes
por: Rehman, Ishita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iln4db8oif7a4rfk7sde2p655i